Alchemia in final stages of demerger

By Tim Dean
Thursday, 13 December, 2012


Alchemia (ASX:ACL) is close to completing its demerger and spin-off of Audeo Oncology and has entered a trading halt that will remain in place until Monday December 17.

Audeo Oncology is about to kick off its IPO, offering 3.25 million shares of common stock at $14-$16 a piece in the hope of raising US$50 million ($49m) to help fund further development of HyACT-based chemotherapy treatments.

Audeo will focus on the development of Alchemia’s HyACT technology, which enhances the delivery of chemotherapy drugs to site of tumours, including HA-irinotecan, which combines with Pfizer’s Camptosar for the treatment of colon cancer.

Alchemia will focus on its existing business manufacturing and distributing generic fondaparinux, which is an FDA approved generic version of Arixtra, marketed by GlaxoSmithKline.

Alchemia’s (ASX:ACL) share price dropped fractionally from 59.5c on Tuesday to 55c just prior to the halt, although it has risen 83% over the last 12 months.

Related Articles

Novel drug candidates found for nerve pain and ischemic disease

The discovery paves the way for potential new treatments for health conditions linked to tissue...

Real-time sequencing helps combat golden staph infections

Tracking bacterial changes during serious Staphylococcus aureus (golden staph) infection...

Single-cell sequencing capability boosted in South Australia

The South Australian Genomics Centre has become the first certified service provider in...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd